Literature DB >> 2527532

Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man.

M Burnier1, V Mooser, J Nussberger, B Waeber, H R Brunner.   

Abstract

1. The haemodynamic and humoral effects of cilazapril, a new angiotensin converting enzyme (ACE) inhibitor, were evaluated in normotensive healthy volunteers. 2. Single oral doses of 1.25, 2.5, 5 and 10 mg of cilazapril inhibited ACE by greater than or equal to 90% and induced the expected pattern of changes of the renin-angiotensin-aldosterone-system. 3. Cilazapril had a long duration of action, since some ACE inhibition was still present 72 h after drug intake. 4. Cilazapril administered intravenously at doses of 5 and 20 micrograms kg-1 for 24 h did not produce any significant effects. 5. During repeated administration of cilazapril for 8 days, no accumulation of cilazaprilat was observed and the clinical tolerance was excellent. 6. In normal volunteers, cilazapril administered orally acts as a potent inhibitor of converting enzyme.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527532      PMCID: PMC1379747          DOI: 10.1111/j.1365-2125.1989.tb03481.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

2.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

3.  An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody.

Authors:  K Poulsen; J Jorgensen
Journal:  J Clin Endocrinol Metab       Date:  1974-11       Impact factor: 5.958

4.  Does the renin-angiotensin system maintain blood pressure in both hypertensive and normotensive subjects? A comparison of propranolol, saralasin and captopril.

Authors:  G A MacGregor; N D Markandu; J E Roulston
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

5.  Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I.

Authors:  J Biollaz; M Burnier; G A Turini; D B Brunner; M Porchet; H J Gomez; K H Jones; F Ferber; W B Abrams; H Gavras; H R Brunner
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

6.  Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.

Authors:  D B Brunner; G Desponds; J Biollaz; I Keller; F Ferber; H Gavras; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

7.  Maintenance of blood pressure by the renin-angiotensin system in normal man.

Authors:  G A MacGregor; N D Markandu; J E Roulston; J C Jones; J J Morton
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

8.  Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor.

Authors:  R Ader; K Chatterjee; T Ports; B Brundage; B Hiramatsu; W Parmley
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

9.  Improvement of chronic congestive heart-failure by oral captopril.

Authors:  G A Turini; H R Brunner; M Gribic; B Waeber; H Gavras
Journal:  Lancet       Date:  1979-06-09       Impact factor: 79.321

10.  The pharmacokinetics and bioavailability of cilazapril in normal man.

Authors:  P E Williams; A N Brown; S Rajaguru; R J Francis; G E Walters; J McEwen; C Durnin
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

View more
  2 in total

Review 1.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

Authors:  F Deget; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.